Table of Contents
<< Previous Issue | Jan 2022 (Vol: 2022, Issue: 1) | Next Issue >> |
- Section: Licensing
-
Genmab Licenses Synaffix’s Antibody-Drug Conjugate Technologies
- Section: Mergers & Acquisitions
-
Takeda Exercises Option to Acquire Adaptate Biotherapeutics
- Section: Opinion & Analysis
-
M&A Activity in 2021 Ends with a Bang
- Section: Research & Development
-
Sumitomo Dainippon Enters Neurology Partnership with Otsuka Pharmaceuticals for US$890 M
-
Pfizer Collaborates with Beam on Gene Editing Technology
-
Eli Lilly Bolsters Metabolic Portfolio with Evotec and Abbisko Collaborations